Trials / Unknown
UnknownNCT05927558
Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study
Salvage Treatment With Glofitamab in Patients Affected by Relapsed/Refractory Non-Hodgkin B-cell Lymphoma: a GIMEMA-FIL Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 96 (estimated)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The goal of this observational study is to evaluate the anti-lymphoma activity of glofitamab, administered according to the Compassionate Use Program, in relapsed/refractory B-NHL patients. The main question it aims to answer is the rate of patients in complete response.
Detailed description
This is an observational multicenter study aimed at assessing the anti-lymphoma activity of glofitamab in relapsed/refractory B cell non-Hodgikin lymphoma patients treated according to the Compassionate Use Program in Italy between March 2022 and September 2023. Patients will be observed for a minimum of 12 months after the last glofitamab administration.
Conditions
Timeline
- Start date
- 2023-12-22
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2023-07-03
- Last updated
- 2023-12-29
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05927558. Inclusion in this directory is not an endorsement.